KPV Peptide: Melanocortin Tripeptide & Inflammation Research

KPV Research Peptide: Melanocortin-Derived Tripeptide and Inflammatory Pathway Research

News

KPV Research Peptide: Melanocortin-Derived Tripeptide and Inflammatory Pathway Research

PE-22-28
$43.00 Select options This product has multiple variants. The options may be chosen on the product page
Adalank
Price range: $49.00 through $79.00 Select options This product has multiple variants. The options may be chosen on the product page
Adamax-984
Price range: $49.00 through $79.00 Select options This product has multiple variants. The options may be chosen on the product page

FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.

KPV is a small research peptide with an outsized research footprint relative to its size. It is a tripeptide, just three amino acids, corresponding to the C-terminal end of the larger signaling molecule alpha-melanocyte-stimulating hormone (alpha-MSH). That fragment retains much of the parent molecule’s studied anti-inflammatory activity, and a substantial body of preclinical literature has examined how it modulates inflammatory signaling.

What makes KPV mechanistically interesting is that much of this activity has been characterized as independent of the classical melanocortin receptors, pointing instead toward an intracellular mode of action.

This article describes the structure and melanocortin origin of KPV, the inflammatory-pathway research it has been used in, its context within blend and topical research formats, and the verification infrastructure relevant to research material.

Research Snapshot

KPV is a synthetic tripeptide composed of lysine, proline, and valine (Lys-Pro-Val), corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone, alpha-MSH(11–13).
In preclinical research, KPV has been characterized as retaining the anti-inflammatory activity associated with the parent alpha-MSH molecule, and it is studied as a modulator of inflammatory signaling pathways (Brzoska et al., 2008).
A defining feature in the literature is that KPV’s activity has been observed even where classical melanocortin-receptor signaling is absent, indicating a substantially receptor-independent, intracellular mechanism (Kannengiesser et al., 2008).
One characterized route of action is uptake into cells via the peptide transporter PepT1, after which KPV has been associated with reduced inflammatory signaling in intestinal epithelial and immune cell research models (Dalmasso et al., 2008).
Pure Health Peptides offers KPV in three carrier formats: Vial (lyophilized powder), Capsule (encapsulated solid), and Liquid / aqueous solution, and as a component of the KLOW blend. Material is sourced from qualified third-party manufacturers; the verification chain, with every lot routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as Pure Health Peptides’ exclusive testing partner, is what Pure Health Peptides owns and stands behind across the catalog.

Introduction

The melanocortin system is one of the more thoroughly studied signaling families in the anti-inflammatory literature, and alpha-MSH sits at its center. KPV is the short C-terminal tail of that molecule. Research interest in the fragment grew from a practical observation: a great deal of alpha-MSH’s characterized anti-inflammatory activity is preserved in this three-residue sequence, which is far simpler to synthesize and study than the full peptide.

This article keeps to the mechanism and the preclinical research. The melanocortin origin, the receptor-independent mode of action, and the inflammatory-pathway models KPV has been examined in are all documented in the published literature, and they are the appropriate frame for research use of this compound.

KPV Structure and Its Melanocortin Origin

KPV is a linear tripeptide with the sequence lysine-proline-valine. In the numbering of the parent hormone, it corresponds to residues 11 to 13 of alpha-MSH, the carboxy-terminal end of that thirteen-residue peptide. Because it is only three amino acids, its identity is unambiguous and easy to confirm analytically, which matters for verification.

The connection to alpha-MSH is the key to why KPV is studied. Alpha-MSH is a melanocortin peptide with well-documented roles in pigmentation and, separately, in the resolution of inflammation. Research into which part of the molecule carried the anti-inflammatory activity pointed to the C-terminal tripeptide, and KPV became the focus of that work. It is worth being precise about the relationship: KPV is derived from a melanocortin, but its studied anti-inflammatory action is not primarily a melanocortin-receptor effect.

The parent alpha-MSH acts substantially through melanocortin receptors, whereas the KPV fragment has been characterized as acting largely through receptor-independent, intracellular routes. This distinction is part of what makes it a distinct research tool rather than simply a smaller version of alpha-MSH. KPV’s melanocortin lineage places it in the same broad signaling family studied through compounds like the melanocortin-receptor agonist PT-141, while its mechanism diverges from that receptor-driven path.

Inflammatory Pathway Research and Mechanism

The core of KPV’s research literature concerns how it modulates inflammatory signaling, and two mechanistic threads define it.

The first is the receptor-independent character of its activity. In murine models of intestinal inflammation, KPV retained anti-inflammatory activity even in animals lacking functional melanocortin-1 receptor signaling, indicating that its effect does not depend on that receptor (Kannengiesser et al., 2008). This directed attention away from the cell surface and toward an intracellular site of action, distinguishing KPV mechanistically from its receptor-signaling parent molecule.

The second thread is how KPV enters cells and what it does once inside. Research has characterized uptake of the tripeptide through PepT1, a di- and tripeptide transporter expressed in intestinal epithelial cells and induced in immune cells during inflammation. In intestinal epithelial and immune cell research models, PepT1-mediated uptake of KPV was associated with reduced activation of pro-inflammatory signaling, including the NF-kB pathway, and with lower expression of inflammatory mediators (Dalmasso et al., 2008). Taken together with the broader review literature on alpha-MSH-derived tripeptides (Brzoska et al., 2008), this positions KPV as a small-molecule research tool for studying how a melanocortin-derived peptide can dampen inflammatory signaling from inside the cell. Throughout this work the framing is mechanistic and preclinical, what has been measured in which research models, rather than any statement about applications outside a controlled research setting. Colitis and inflammatory bowel disease appear in this literature strictly as established animal models of inflammation used to probe the mechanism, not as conditions addressed by the compound.

KPV in Blend and Topical Research Context

Within the Pure Health Peptides catalog, KPV appears both as a standalone research peptide, offered in Vial, Capsule, and Liquid / aqueous solution carrier formats, and as a component of blend and topical research formats, which reflects how it is studied alongside other signaling peptides.

It is one of the compounds in the KLOW blend, where it is combined with tissue-signaling peptides including BPC-157, GHK-Cu, and TB-500. Blend research examines compounds studied for complementary signaling roles in the same preparation, and KPV’s inflammatory-pathway profile is what situates it there. Its dermal and barrier-research associations also connect it to the broader Topical Systems research format, and its inflammatory-signaling focus places it adjacent to immunomodulatory compounds such as Thymosin Alpha-1. Across these formats, the reason a small tripeptide earns attention is consistent: a simple, well-defined sequence with a characterized inflammatory-signaling mechanism is a tractable tool for research.

Sourcing, Verification, and Lot-Level Testing

KPV in the Pure Health Peptides catalog is sourced from qualified third-party manufacturers as strictly compliant research material, offered in Vial, Capsule, and Liquid / aqueous solution carrier formats. Pure Health Peptides does not manufacture material directly. What Pure Health Peptides owns and stands behind across the catalog is the third-party verification chain.

Every production lot is routed through independent, accredited testing by its exclusive testing partner Ethos Analytics under ISO/IEC 17025 accreditation, with the result published as a lot-specific Certificate of Analysis. The standard COA panel reports peptide identity verified by HPLC and mass spectrometry per USP <621>, comparing the measured mass against the theoretical mass for the three-residue sequence, alongside purity, quantity, heavy metals screening by ICP-MS per USP <233>, endotoxin testing per USP <85>, and microbiological screening per USP <61> and USP <62>. Lot-level COAs are accessible through the publicly browsable COA Library (Vial COAs | Capsule COAs | Liquid COAs).

Because KPV is a short, defined tripeptide, identity confirmation by mass spectrometry is straightforward, which makes lot-level verification a clear signal of exactly what the material is.

The Direction of Melanocortin-Derived Peptide Research

Research into alpha-MSH and its fragments continues, and KPV remains one of the more studied members of that family precisely because it separates a specific activity, inflammatory-pathway modulation, from the receptor signaling of the parent molecule. That separation is what keeps it a useful mechanistic probe: it lets researchers study a melanocortin-derived anti-inflammatory action without the confounding effects of full melanocortin-receptor engagement.

The compound also anchors a cluster of research organized around inflammatory and tissue-signaling peptides, sitting alongside the blend and dermal-research compounds it is formulated with. Across that cluster, the common thread is how small peptides modulate signaling in research models, and how a simple, verifiable sequence can serve as a defined tool for that work.

Quality verification is foundational to all of it. Mechanistic and pathway studies depend on confidence that the compound under investigation is exactly the defined tripeptide and free of confounding contaminants, and the lot-level COA infrastructure described above is built to support that requirement.

FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.

Frequently Asked Research Questions

What is KPV, and what is its structure?

KPV is a synthetic tripeptide composed of lysine, proline, and valine (Lys-Pro-Val). It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone, alpha-MSH(11–13), which is the origin of its research interest.

Is KPV a melanocortin, and does it act through melanocortin receptors?

KPV is derived from the melanocortin alpha-MSH, but its studied anti-inflammatory activity has been characterized as largely independent of the classical melanocortin receptors. In murine research models, the activity persisted even without functional melanocortin-1 receptor signaling, pointing to an intracellular mechanism (Kannengiesser et al., 2008).

What inflammatory-pathway mechanism has KPV been studied for?

Research has characterized uptake of KPV into cells via the peptide transporter PepT1, after which it was associated with reduced activation of pro-inflammatory signaling, including the NF-kB pathway, in intestinal epithelial and immune cell research models (Dalmasso et al., 2008). This is studied strictly as a preclinical research mechanism.

Why does KPV appear in blends like KLOW?

KPV is studied alongside tissue-signaling peptides such as BPC-157, GHK-Cu, and TB-500 for their complementary signaling roles in research preparations. Its inflammatory-pathway profile is what situates it within the KLOW blend and adjacent topical research formats.

How is KPV identity verified at the lot level?

Peptide identity is confirmed by HPLC coupled with mass spectrometry per USP <621>, comparing the measured mass against the theoretical mass for the three-residue sequence. Each lot is routed through independent, accredited testing by its exclusive testing partner Ethos Analytics under ISO/IEC 17025 accreditation, with the result reported on a lot-specific Certificate of Analysis.